Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003129 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
A Phase 2 study of Bladder Cancer, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 10
- Study locations
NCT00003129 is a Phase 2 study of Bladder Cancer that has completed, run by Eastern Cooperative Oncology Group. The registered enrollment target is 75 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT00003129, a Phase 2 study of Bladder Cancer, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 10
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with early-stage bladder cancer that has not responded to BCG therapy.
Conditions Studied
Interventions
- DRUG valrubicin
Study Locations (10)
Wisconsin
- CCOP - Green Bay - Green Bay
- Veterans Affairs Medical Center - Madison - Madison
- University of Wisconsin Comprehensive Cancer Center - Madison
- Medical College of Wisconsin - Milwaukee
- Veterans Affairs Medical Center - Milwaukee (Zablocki) - Milwaukee
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- CCOP - MainLine Health - Wynnewood
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- CCOP - Carle Cancer Center - Urbana
New Jersey
- Veterans Affairs Medical Center - East Orange - East Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 1998-09-01 |
| Est. Completion | 2009-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003129
The ClinicalTrials.gov registry entry for NCT00003129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which valrubicin is the first listed.
NCT00003129 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Wisconsin, Pennsylvania, Florida.
Frequently Asked Questions
What is clinical trial NCT00003129 about?
NCT00003129 is a clinical study titled "Chemotherapy in Treating Patients With Early-Stage Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy in treating patients with early-stage bladder cancer that has not responded to BCG therapy.
What is the current status of trial NCT00003129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 1998-09-01. Estimated completion is 2009-05-01.
What conditions does trial NCT00003129 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00003129?
The interventions under investigation include: valrubicin (DRUG).
Who is sponsoring clinical trial NCT00003129?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003129 being conducted?
This trial has 10 study locations across Florida, Illinois, New Jersey, Pennsylvania, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.